CervoMed (NasdaqCM:CRVO) Conference October 22, 2025 11:25 AM ET Company ParticipantsMatt Wenton - Chief Commercial and Business OfficerModeratorWelcome back, everyone. We have CervoMed Inc. they trade on the Nasdaq under the symbol CRBO. It's a clinical-stage company focused on developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38 MAP kinase alpha. Please welcome Chief Commercial and Business Officer Matt Wenton. Matt, sorry for mispronouncing all ...

BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025. Presentation DetailsFormat: Corporate PresentationDate: Wednesday, October 22, 2025Time: 11:25 – 11:55 AM ETWebcast Link: https://goto ...

CervoMed Inc. (NASDAQ:CRVO) on Wednesday shared additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies (DLB).The results are based on the final analyses of the RewinD-LB trial, conducted after the August 2025 database lock for the full 48-week trial (16 weeks placebo-controlled (Initial Phase), followed by a 32-week neflamapimod-only extension (Extension Phase)).In the subset of participants whose plasma ptau181 levels were below 21 pg/mL at screening, results includ ...

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer’s disease (AD) co-pathology Significant reduction in plasma levels of a well-established biomarker of neurodegeneration, plasma glial fibrillary acidic protein (GFAP), correlated to treatment response assessed by CDR-SB CervoMed anticipates U.S. Food and Drug Administration (FDA) fee ...

Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readinessBOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnolog ...

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025. Panel DetailsTitle: “Small Firms Tackling Blockbuster Indications”Date: Thursday, October ...

BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were highlighted in a presentation on advances in DLB drug development by Dr. James Galvin at the 150th Annual American Neurological Association (ANA) conference held Sep ...

CervoMed (NasdaqCM:CRVO) FY Conference September 08, 2025 02:00 PM ET Company ParticipantsNone - ExecutiveConference Call ParticipantsNone - AnalystNoneSay, clinically, they have dementia with Lewy bodies, but they have no evidence of AD pathology on top of it. Within the last three years, this test has become established as a way to act as a surrogate for that PET scan, and use that to say that if if you're low enough on the test with you have enriched for, you are unlikely to have AD pathology on top of t ...

Exhibit 99.1 CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer's disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflam ...

Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer's disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acid ...